Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298944> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4286298944 endingPage "e17579" @default.
- W4286298944 startingPage "e17579" @default.
- W4286298944 abstract "e17579 Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent (PSR) ovarian cancer remains controversial. This single arm phase 2 study (OPEB-01) evaluated a triple combination regimen with olaparib, bevacizumab, and pembrolizumab as 2nd-line maintenance treatment in BRCA non-mutated, PSR ovarian cancer. Methods: Women with PSR ovarian cancer who had a partial or complete response to their most recent platinum-based regimen were eligible. Patients received olaparib 300mg PO bid daily, bevacizumab 15mg/kg IV q3w, and pembrolizumab 200mg IV q3w until progressive disease or unacceptable toxicity. The primary endpoint of the study was 6-month PFS rate. A simon 2-stage design was utilized. Target accrual was 22 patients in the first stage; 13 or more patients with non-progressive disease at 6 months was required to proceed to second stage. Results: 22 patients were enrolled at the first stage. Median age was 60 years old and most of the patients (90.9%) had high-grade serous carcinoma. Secondary cytoreductive surgery was performed in 6 (27.3%) patients. The objective response rate (ORR) was 68.2% and the disease control rate (DCR) was 90.9%. At the time of data analysis (data cutoff Jan 19 2022), 20 (90.9%) had non-progressive disease at 6 months. No grade 4 adverse events were reported and no treatment related adverse events leading to treatment discontinuation was observed. Additional correlative data regarding homologous recombination deficiency and PD-L1 will be presented at the meeting. Conclusions: OPEB-01 is the first trial to suggest the potential benefit of triple combination maintenance in BRCA wild-type patients. These combinations showed a manageable safety profile. Accrual is ongoing in the second stage. Clinical trial information: NCT4361370." @default.
- W4286298944 created "2022-07-21" @default.
- W4286298944 creator A5023387547 @default.
- W4286298944 creator A5024381278 @default.
- W4286298944 creator A5027873499 @default.
- W4286298944 creator A5035176942 @default.
- W4286298944 creator A5046657476 @default.
- W4286298944 creator A5055261519 @default.
- W4286298944 creator A5057234589 @default.
- W4286298944 creator A5059673967 @default.
- W4286298944 creator A5061006522 @default.
- W4286298944 creator A5081238524 @default.
- W4286298944 creator A5084899098 @default.
- W4286298944 date "2022-06-01" @default.
- W4286298944 modified "2023-10-02" @default.
- W4286298944 title "Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in <i>BRCA </i>non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01." @default.
- W4286298944 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e17579" @default.
- W4286298944 hasPublicationYear "2022" @default.
- W4286298944 type Work @default.
- W4286298944 citedByCount "1" @default.
- W4286298944 countsByYear W42862989442023 @default.
- W4286298944 crossrefType "journal-article" @default.
- W4286298944 hasAuthorship W4286298944A5023387547 @default.
- W4286298944 hasAuthorship W4286298944A5024381278 @default.
- W4286298944 hasAuthorship W4286298944A5027873499 @default.
- W4286298944 hasAuthorship W4286298944A5035176942 @default.
- W4286298944 hasAuthorship W4286298944A5046657476 @default.
- W4286298944 hasAuthorship W4286298944A5055261519 @default.
- W4286298944 hasAuthorship W4286298944A5057234589 @default.
- W4286298944 hasAuthorship W4286298944A5059673967 @default.
- W4286298944 hasAuthorship W4286298944A5061006522 @default.
- W4286298944 hasAuthorship W4286298944A5081238524 @default.
- W4286298944 hasAuthorship W4286298944A5084899098 @default.
- W4286298944 hasConcept C104317684 @default.
- W4286298944 hasConcept C121608353 @default.
- W4286298944 hasConcept C126322002 @default.
- W4286298944 hasConcept C141071460 @default.
- W4286298944 hasConcept C143998085 @default.
- W4286298944 hasConcept C182979987 @default.
- W4286298944 hasConcept C185592680 @default.
- W4286298944 hasConcept C197934379 @default.
- W4286298944 hasConcept C2776694085 @default.
- W4286298944 hasConcept C2777701055 @default.
- W4286298944 hasConcept C2777802072 @default.
- W4286298944 hasConcept C2778375690 @default.
- W4286298944 hasConcept C2778822529 @default.
- W4286298944 hasConcept C2779962180 @default.
- W4286298944 hasConcept C2780057760 @default.
- W4286298944 hasConcept C2780194787 @default.
- W4286298944 hasConcept C2780427987 @default.
- W4286298944 hasConcept C2781413609 @default.
- W4286298944 hasConcept C535046627 @default.
- W4286298944 hasConcept C55493867 @default.
- W4286298944 hasConcept C61943457 @default.
- W4286298944 hasConcept C71924100 @default.
- W4286298944 hasConcept C82381507 @default.
- W4286298944 hasConceptScore W4286298944C104317684 @default.
- W4286298944 hasConceptScore W4286298944C121608353 @default.
- W4286298944 hasConceptScore W4286298944C126322002 @default.
- W4286298944 hasConceptScore W4286298944C141071460 @default.
- W4286298944 hasConceptScore W4286298944C143998085 @default.
- W4286298944 hasConceptScore W4286298944C182979987 @default.
- W4286298944 hasConceptScore W4286298944C185592680 @default.
- W4286298944 hasConceptScore W4286298944C197934379 @default.
- W4286298944 hasConceptScore W4286298944C2776694085 @default.
- W4286298944 hasConceptScore W4286298944C2777701055 @default.
- W4286298944 hasConceptScore W4286298944C2777802072 @default.
- W4286298944 hasConceptScore W4286298944C2778375690 @default.
- W4286298944 hasConceptScore W4286298944C2778822529 @default.
- W4286298944 hasConceptScore W4286298944C2779962180 @default.
- W4286298944 hasConceptScore W4286298944C2780057760 @default.
- W4286298944 hasConceptScore W4286298944C2780194787 @default.
- W4286298944 hasConceptScore W4286298944C2780427987 @default.
- W4286298944 hasConceptScore W4286298944C2781413609 @default.
- W4286298944 hasConceptScore W4286298944C535046627 @default.
- W4286298944 hasConceptScore W4286298944C55493867 @default.
- W4286298944 hasConceptScore W4286298944C61943457 @default.
- W4286298944 hasConceptScore W4286298944C71924100 @default.
- W4286298944 hasConceptScore W4286298944C82381507 @default.
- W4286298944 hasIssue "16_suppl" @default.
- W4286298944 hasLocation W42862989441 @default.
- W4286298944 hasOpenAccess W4286298944 @default.
- W4286298944 hasPrimaryLocation W42862989441 @default.
- W4286298944 hasRelatedWork W2944466214 @default.
- W4286298944 hasRelatedWork W2994977341 @default.
- W4286298944 hasRelatedWork W3090114554 @default.
- W4286298944 hasRelatedWork W3113307403 @default.
- W4286298944 hasRelatedWork W3126466062 @default.
- W4286298944 hasRelatedWork W3204368990 @default.
- W4286298944 hasRelatedWork W4205682580 @default.
- W4286298944 hasRelatedWork W4283025800 @default.
- W4286298944 hasRelatedWork W4286298944 @default.
- W4286298944 hasRelatedWork W4297497039 @default.
- W4286298944 hasVolume "40" @default.
- W4286298944 isParatext "false" @default.
- W4286298944 isRetracted "false" @default.
- W4286298944 workType "article" @default.